Heidegger Isabel, Kesch Claudia, Kretschmer Alexander, Tsaur Igor, Ceci Francesco, Valerio Massimo, Tilki Derya, Marra Giancarlo, Preisser Felix, Fankhauser Christian D, Zattoni Fabio, Chiu Peter, Puche-Sanz Ignacio, Olivier Jonathan, van den Bergh Roderik C N, Kasivisvanathan Veeru, Pircher Andreas, Virgolini Irene, Gandaglia Giorgio
Professor of Urology, Department of Urology, Medical University Innsbruck, 6020 Innsbruck, Austria.
Department of Urology, Essen University Hospital, Essen, Germany.
Ther Adv Med Oncol. 2022 Mar 5;14:17588359221081922. doi: 10.1177/17588359221081922. eCollection 2022.
Radioligand therapy with Lutetium-177 (177Lu)-Prostate-specific membrane antigen (PSMA) has shown to prolong survival in metastatic castration resistant prostate cancer (mCRPC). One of the major challenges for clinicians in the future is to select those patients who would benefit most from this therapy to position it in the treatment landscape of mCRPC. This, in turn, will lead to the delivery of personalized therapies. In this narrative review article we summarize recent studies investigating both predictive and prognostic clinical, imaging-based, and molecular biomarkers to predict treatment response to 177Lu-PSMA-617 radioligand therapy with the aim of identifying men who should be considered for this approach. Of note, the evidence on the role of biomarkers currently relies on small retrospective trials and their validation in larger prospective cohorts is necessary before these results can be translated in the clinical practice.
用镥-177（¹⁷⁷Lu）-前列腺特异性膜抗原（PSMA）进行放射性配体治疗已显示可延长转移性去势抵抗性前列腺癌（mCRPC）患者的生存期。未来临床医生面临的主要挑战之一是选择那些能从该治疗中获益最大的患者，以便将其纳入mCRPC的治疗方案中。这反过来又将促成个性化治疗的实施。在这篇叙述性综述文章中，我们总结了近期的研究，这些研究调查了预测性和预后性的临床、基于影像以及分子生物标志物，以预测对¹⁷⁷Lu-PSMA-617放射性配体治疗的反应，目的是确定哪些男性患者应考虑采用这种治疗方法。值得注意的是，目前关于生物标志物作用的证据依赖于小型回顾性试验，在这些结果能够应用于临床实践之前，需要在更大规模的前瞻性队列中对其进行验证。
